Understanding the inflammatory in pneumonia and sepsis - Results of the genetic and inflammatory markers of sepsis (GenIMS) study

被引:615
作者
Kellum, John A.
Kong, Lan
Fink, Mitchell P.
Weissfeld, Lisa A.
Yealy, Donald M.
Pinsky, Michael R.
Fine, Jonathan
Krichevsky, Alexander
Delude, Russell L.
Angus, Derek C.
机构
[1] Univ Pittsburgh, Sch Med, Dept Crit Care Med, CRISMA Lab, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15261 USA
[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA
[4] Norwalk Hosp, Pulm & Crit Care Med Sect, Beulah Hinds Ctr Lung Studies, Norwalk, CT 06856 USA
关键词
D O I
10.1001/archinte.167.15.1655
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Severe sepsis is common and frequently fatal, and community-acquired pneumonia ( CAP) is the leading cause. Although severe sepsis is often attributed to uncontrolled and unbalanced inflammation, evidence from humans with infection syndromes across the breadth of disease is lacking. In this study we describe the systemic cytokine response to pneumonia and determine if specific patterns, including the balance of proinflammatory and anti-inflammatory markers, are associated with severe sepsis and death. Methods: This is a cohort study of 1886 subjects hospitalized with CAP through the emergency departments in 28 US academic and community hospitals. We defined severe sepsis as CAP complicated by new-onset organ dysfunction, following international consensus conference criteria. We measured plasma tumor necrosis factor, IL-6 ( interleukin 6), and IL-10 levels daily for the first week and weekly thereafter. Our main outcome measures were severe sepsis and 90-day mortality. Results: A total of 583 patients developed severe sepsis (31%), of whom 149 died (26%). Systemic cytokine level elevation occurred in 82% of all subjects with CAP. Mean cytokine concentrations were highest at presentation, declined rapidly over the first few days, but remained elevated throughout the first week, beyond resolution of clinical signs of infection. Cytokine levels were highest in fatal severe sepsis and lowest in CAP with no severe sepsis. Unbalanced (high/low) cytokine patterns were unusual (4.6%) and not associated with decreased survival. Highest risk of death was with combined high levels of the proinflammatory IL-6 and anti-inflammatory IL-10 cytokine activity (hazard ratio, 20.5; 95% confidence interval, 10.8-39.0) (P <. 001). Conclusions: The circulating cytokine response to pneumonia is heterogeneous and continues for more than a week after presentation, with considerable overlap between those who do and do not develop severe sepsis. Unbalanced activation is uncommon, and mortality is highest when both proinflammatory and anti-inflammatory cytokine levels are high.
引用
收藏
页码:1655 / 1663
页数:9
相关论文
共 49 条
  • [1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [2] Surviving intensive care: a report from the 2002 Brussels Roundtable
    Angus, DC
    Carlet, J
    [J]. INTENSIVE CARE MEDICINE, 2003, 29 (03) : 368 - 377
  • [3] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [4] Prolonged inhibition of nitric oxide synthesis in severe septic shock: A clinical study
    Avontuur, JAM
    Nolthenius, RPT
    van Bodegom, JW
    Bruining, HA
    [J]. CRITICAL CARE MEDICINE, 1998, 26 (04) : 660 - 667
  • [5] The effects of ibuprofen on the physiology and survival of patients with sepsis
    Bernard, GR
    Wheeler, AP
    Russell, JA
    Schein, R
    Summer, WR
    Steinberg, KP
    Fulkerson, WJ
    Wright, PE
    Christman, BW
    Dupont, WD
    Higgins, SB
    Swindell, BB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (13) : 912 - 918
  • [6] Why sepsis trials fail
    Bone, RC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (07): : 565 - 566
  • [7] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [8] SEPSIS AND CONTROLLED CLINICAL-TRIALS - THE ODYSSEY CONTINUES
    BONE, RC
    [J]. CRITICAL CARE MEDICINE, 1995, 23 (08) : 1313 - 1315
  • [9] Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)
    Bone, RC
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (08) : 680 - 687
  • [10] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383